Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
Frequently asked questions
What sector does Healios K K (4593) operate in?
Healios K K belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Healios K K (4593) current stock price?
As of the latest data, Healios K K stock price is ¥284, with a previous close of ¥288. Healios K K lost -¥4 in the last trading session, representing a -1.39% loss.
What is Healios K K (4593) current market capitalization?
Healios K K market cap is approximately 38.34 billion.
What is Healios K K (4593) Earnings Per Share (EPS)?
The trailing EPS is ¥1, and the forward EPS is -¥23.
What is Healios K K (4593) Price-to-Earnings (P/E) ratio?
Healios K K current P/E ratio is 273.08.
What is Healios K K (4593) EBITDA?
Healios K K EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.21 billion.
Does Healios K K (4593) pay dividends?
No. Healios K K does not pay a dividend.
How did Healios K K (4593) perform in its most recent earnings report?
In the last report (June 30, 2026), Healios K K posted an EPS surprise of 199.02% and a revenue surprise of -68.89%.
What is Healios K K (4593) beta (volatility) score?
Healios K K has a beta of 1.420, suggesting it is more volatile than the market.
